☆ 4.8 Article

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

GUT (2014)

期刊

GUT

卷 63, 期 4, 页码 567-577

出版社

BMJ PUBLISHING GROUP

DOI: 10.1136/gutjnl-2012-302853

关键词

类别

Gastroenterology & Hepatology

资金

Deutsche Forschungsgemeinschaft (DFG) [BR 1912/6-1, BE 4490/2-1]
Else-Kroner-Fresenius-Stiftung (Else Kroner-Exzellenzstipendium) [2010_EKES.32]

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

摘要

Background We analysed incidence, predictors, histological features and specific treatment options of anti-tumour necrosis factor alpha (TNF-alpha) antibody-induced psoriasiform skin lesions in patients with inflammatory bowel diseases (IBD). Design Patients with IBD were prospectively screened for anti-TNF-induced psoriasiform skin lesions. Patients were genotyped for IL23R and IL12B variants. Skin lesions were examined for infiltrating Th1 and Th17 cells. Patients with severe lesions were treated with the anti-interleukin (IL)-12/IL-23 p40 antibody ustekinumab. Results Among 434 anti-TNF-treated patients with IBD, 21 (4.8%) developed psoriasiform skin lesions. Multiple logistic regression revealed smoking (p=0.007; OR 4.24, 95% CI 1.55 to 13.60) and an increased body mass index (p=0.029; OR 1.12, 95% CI 1.01 to 1.24) as main predictors for these lesions. Nine patients with Crohn's disease and with severe psoriasiform lesions and/or anti-TNF antibody-induced alopecia were successfully treated with the anti-p40-IL-12/IL-23 antibody ustekinumab (response rate 100%). Skin lesions were histologically characterised by infiltrates of IL-17A/IL-22-secreting T helper 17 (Th17) cells and interferon (IFN)-gamma-secreting Th1 cells and IFN-alpha-expressing cells. IL-17A expression was significantly stronger in patients requiring ustekinumab than in patients responding to topical therapy (p=0.001). IL23R genotyping suggests disease-modifying effects of rs11209026 (p.Arg381Gln) and rs7530511 (p.Leu310Pro) in patients requiring ustekinumab. Conclusions New onset psoriasiform skin lesions develop in nearly 5% of anti-TNF-treated patients with IBD. We identified smoking as a main risk factor for developing these lesions. Anti-TNF-induced psoriasiform skin lesions are characterised by Th17 and Th1 cell infiltrates. The number of IL-17A-expressing T cells correlates with the severity of skin lesions. Anti-IL-12/IL23 antibody therapy is a highly effective therapy for these lesions.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.8

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Anti-ICOS mAb Targets Pathogenic IL-17A-expressing Cells in Canine Model of Chronic GVHD

Maura H. Parker, Diane Stone, Kraig Abrams, Melissa Johnson, Noa Granot, Rainer Storb

Summary: Chronic graft-versus-host disease (GVHD) is a significant issue in transplant patients, and targeting specific T-cell populations like CD4(+) and CD8(+) T cells may be crucial in developing effective treatments for the disease. Treatment with anti-inducible costimulator (ICOS) monoclonal antibodies showed promising results in transiently relieving symptoms and prolonging survival in dogs with chronic GVHD, particularly targeting IL-17A(+) cells, but further research is needed to control both CD4(+) and CD8(+) T cells for better outcomes.

TRANSPLANTATION (2021)